期刊
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
卷 13, 期 4, 页码 458-468出版社
AMER SCIENTIFIC PUBLISHERS
DOI: 10.1166/jbn.2017.2358
关键词
EGFR-TKI; Iron Oxide Nanoparticles; Combination Therapy; ErbB3; PI3K/AKT
资金
- national natural science foundation, China [81472695, 81402249, 81272255]
- Natural science foundation, China of Hunan [2015JJ2181]
- Wu Jieping Medical Foundation clinical research special fund [320.6750.13125]
- Project of Innovation-driven Plan of Central South University [2016CX023]
Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases. EGFR tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib and gefitinib, are currently approved for the management of NSCLC. However, primary and acquired resistances to EGFR-TKIs are the major obstacles in the treatment of NSCLC. These resistances have been associated with the development of secondary mutations in EGFR or continued oncogenic signaling despite TKI treatment. In this study, NSCLC cells with wild-type EGFR, A549, H460, H358, H157 which do not respond to EGFR-TKIs, were used. We investigated whether a combination therapy of erlotinib plus iron oxide nanoparticles (IONPs) could sensitize NSCLC cells to erlotinib-induced cancer inhibition. In the 4 NSCLC cells investigated, erlotinib and IONPs combination therapy obviously inhibited NSCLC proliferation in vitro and in vivo, compared with erlotinib treatment alone. This effect was not dependent on erlotinib dose. Activation of ErbB3 was observed in these refractory NSCLC cells. Combined with IONPs, erlotinib could block ErbB3 activity and induce the expression of PTEN, which in turn inhibited the downstream PI3K-AKT signaling pathway. These data demonstrate the therapeutic potential of biocompatible IONPs in combination with EGFR-TKIs in NSCLC, thus expanding and repurposing the current therapy for NSCLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据